Altrenogest

Bezeichnung:Altrenogest

CAS-Nr850-52-2

Englisch Name:Altrenogest

CBNumberCB7211951

SummenformelC21H26O2

Molgewicht310.44

MOL-Datei850-52-2.mol

Synonyma

Altrenogest

Altrenogest physikalisch-chemischer Eigenschaften

Schmelzpunkt	120°
alpha	D20 -72° (c = 0.5 in ethanol)
Siedepunkt	390.58°C (rough estimate)
Dichte	1.0865 (rough estimate)
Brechungsindex	1.4900 (estimate)
storage temp.	Sealed in dry,2-8°C
Löslichkeit	DMF: 2 mg/ml; DMSO: 0.1 mg/ml; Ethanol: 20 mg/ml; Ethanol:PBS (pH 7.2)(1:2): 0.3 mg/ml
pka	14.59±0.40(Predicted)
Aggregatzustand	Solid
Farbe	White to Yellow
Merck	14,319
InChI	InChI=1/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/s3
InChIKey	VWAUPFMBXBWEQY-ANULTFPQSA-N
SMILES	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@@]3([H])[C@]1([H])CC[C@@]2(O)CC=C \|&1:1,14,16,20,r\|

Sicherheit

WGK Germany	3
RTECS-Nr.	KG7745000
HS Code	2937.23.5050

Gefahreninformationscode (GHS)

Altrenogest Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
Pale Yellow Solid
Verwenden
Altrenogest can be used as a synthetic progestational agent used in veterinary medicine for the control of estrus in mares and antineoplastic.
Definition
ChEBI: Altrenogest is a 3-hydroxy steroid.
Trademarks
REGUMATE (Roussel-UCLAF, France).
Nebenwirkungen
People exposed to altrenogest products have potential health risks. Reproductive adverse effects reported in women and girls include abnormal or absent menstrual cycles, and in men include decreased libido. Other adverse effects reported after exposure include headaches, fever, abdominal pain, nausea, diarrhea, vomiting, and rashes.
Altrenogest causes essentially no side effects in mares, and it may be used for prolonged periods.
Veterinary Drugs and Treatments
Altrenogest (Regu-Mate) is indicated (labeled) to suppress estrus in mares to allow a more predictable occurrence of estrus following withdrawal of the drug. It is used clinically to assist mares to establish normal cycles during the transitional period from anestrus to the normal breeding season often in conjunction with an artificial photoperiod. It is more effective in assisting in pregnancy attainment later in the transition period. Some authors (Squires et al. 1983) suggest selecting mares with considerable follicular activity (mares with one or more follicles 20 mm or greater in size) for treatment during the transitional phase. Mares that have been in estrus for 10 days or more and have active ovaries are also considered excellent candidates for progestin treatment.
Altrenogest is effective in normally cycling mares for minimizing the necessity for estrus detection, for the synchronization of estrus, and permitting scheduled breeding. Estrus will ensue 2 – 5 days after treatment is completed and most mares ovulate between 8 – 15 days after withdrawal. Altrenogest is also effective in suppressing estrus expression in show mares or mares to be raced. Although the drug is labeled as contraindicated during pregnancy, it has been demonstrated to maintain pregnancy in oophorectomized mares and may be of benefit in mares that abort due to sub-therapeutic progestin levels.
The product Matrix is labeled for synchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with altrenogest results in estrus (standing heat) 4-9 days after completion of the 14-day treatment period.
Altrenogest has been used in dogs for luteal insufficiency and as a treatment to prevent premature delivery.

Altrenogest Upstream-Materialien And Downstream Produkte

Altrenogest Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

850-52-2, Altrenogest Verwandte Suche:

Send Inquriy